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Objectives: Determine if the mutation and complications could be risk
factors for atelectasis and assessment of exacerbations.
Methods: Retrospective study in 14 Spanish monographic units of CF and
Jena University Hospital. Including CF patients who have suffered
atelectasis (case group) and a control group. Variables: mutations,
comorbidities, pulmonary complications and exacerbations.
Results: 110 patients. 62.7% women. No demographic differences between
groups: sex, weight, height and age.
• Mutations: heterozygous F508del (60% cases, 52.7% controls). No
differences between groups.
• Comorbidities: No differences in pancreatic insufficiency and CFRD.
• Pulmonary complications: No differences in hemoptysis, emboliza-
tion, pneumothorax and chronic bronchial infection in the last year.
• ABPA–>more associated in the group with atelectasis (p = 0.001).
• Exacerbations:
• Comparison mild-moderate and severe in the last year between
groups–> higher average number of severe exacerbations in cases
(1.09 ± 1.43) versus controls (0.31 ± 0.77) (p = 0.001).
• Relationship between the number of exacerbations in the last year
and in the year prior to atelectasis (p = 0.026,coefficient 0.309) and
in the year after it (p = 0.001,coefficient 0.455), as well as between
the number of exacerbations in the year before and after atelectasis
(p < 0.001, coefficient 0.477).
• No radiological improvement: greater average number of exacerba-
tions in the year after atelectasis (4.67 ± 3.51) than those who
improved (2.68 ± 2.32) (p = 0.037).
• No clinical improvement: higher average number of exacerbations in
the following year (4.73 ± 3.39) than those who improved
(2.92 ± 2.76) (p = 0.035).
Conclusions: - ABPA as a possible risk factor for the appearance of
atelectasis
- Significant increase in exacerbations:
1. severe in the last year between groups,
2. between the year before and after the atelectasis with respect to
the last year,
3. between the year before and after the atelectasis,
4. no clinical-radiological improvement.
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Objective: Optimisation of Dornase alpha therapy for cystic fibrosis (CF) in
paediatric practice.
Material and methods: The level of nuclease activity was measured in 35
patients after inhalation of Dornase alpha.
Results: An increase in the level of nuclease activity of blood plasma after
inhalation of Dornase alpha by patients with CF was obtained. High
variability was observed in the dynamics of changes in the level of nuclease
activity during therapy with the inhaled drug Dornase alpha. Depending
on the period of reaching the peak level of nuclease activity after inhalation
of the drug (Tmax), the patientswere divided into 4 groups: Tmax 1.5 hours
(1 group), Tmax 3.0 hours (2 group), Tmax 4.5 hours (3 group), Tmax 6.0
hours (4 group). The change in the area under the curve (AUC) “nuclease
activity-time” (ng*hour/ml) in 88.59% of cases and the PK parameter —
peak nuclease activity (Cmax, ng/ml) in 89.17% is determined by the
parameter - BMI (p < 0.0001). Higher AUC values nuclease activity-time
(ng*hour/ml) were obtained in girls. Significantly lower values AUC
“nuclease activity-time” (ng*hour/ml) and peak levels of nuclease activity
were found in patients who received inhaled glucocorticosteroids (ICS) in
therapy (p < 0.05).
Conclusion: The level of nuclease activity during inhalation of Dornase alfa
in patients with CF depends on gender, BMI and ICS therapy, which should
be taken into account when prescribing this drug. The inhalation time can
be selected according to the possibilities of the patient’s daily routine.
Further study of PK Dornase alphawill help in choosing the optimal dosage
regimen taking into account the use of other inhaled drugs and in the
development of more effective kinesitherapy regimens. Also, the data
obtained will help determine the possibilities of using this drug from the
point of view of other links in the pathogenesis of CF associated with free
DNA.
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Objectives: There are few studies about survival in patients with Cystic
Fibrosis (CF) under oxygen therapy (OT). Considering its clinical meaning
and impact on patients’ lifestyle, we aimed to determine how OT is
associated with known prognostic factors and with lung transplantation
(LTx) and death (D).
Methods:We considered patients ≤50 years registered in the ECFSPR from
2008 to 2017. An illness-death multi-state model was fitted, denoting LTx
as intermediate state. Cox’s proportional hazard models were fitted using
age as time scale and left truncation corresponding to age at entry into
ECFSPR. Models were used to estimate transition intensities and OT hazard
ratio (HR), adjusted for known prognostic factors (age, sex, insulin,
Pseudomonas aeruginosa (Pa), Burkholderia cepacia (BC), BMI and FEV1%
predicted).
Results: 58576 patients were included in the analysis and 7627 (13%) had
OT during the follow-up. 27587 (47.6%) were females, 35784 (61.1%) were
<18 yrs old, 5228 (10.6%) had FEV1 <40%predicted, 5185 (9.5%) were
underweight (BMI z score <−2), 6386 (10.9%) used insulin, 14037 (26.9%)
had Pa, 1236 (2.4%) had BC.
During the follow-up, 2509 patients had LTx and 3091 patients died: 2338
before and 753 after LTx.
From the multi-state model, patients in OT have higher probability of
having LTx (HR = 12.9, 95% CI: 11.6–14.4). The HRof death for patients in OT
is 7.8 (95% CI: 6.9–8.7) before LTX, while it is 1.4 (95% CI: 1.2–1.7) after LTx.
Conclusions: The need for oxygen therapy represents a turning point in
patients’ life, decreasing their chances of survival, with implications in the
post LTX period yet. UndoubtedlyOTshould be considered as amarker of CF
disease severity, and patients with a supplemental oxygen requirement
should have prompt and fully clinical reassessment. Preventing respiratory
failure with oxygen requirement remains one of the main goals of CF care.
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Objectives: There is established evidence that poor nutrition status and
lowactivity levels are accompanied byhigh inflammation burden and rapid
decline of lung function. Altered production of pro-resolving lipid
mediators, as Resolvin-D1 (RvD1), play a key role in chronic inflammation
of CF pathogenesis.
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